Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer
1
Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
2
UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, CA 90095, USA
3
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
4
Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA 90095, USA
5
The VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(1), 305; https://doi.org/10.3390/ijms22010305
Received: 6 November 2020
/
Revised: 15 December 2020
/
Accepted: 18 December 2020
/
Published: 30 December 2020
(This article belongs to the Section Molecular Pharmacology)
One of the major challenges in the treatment of cancer are differential responses of patients to existing standard of care anti-cancer drugs. These differential responses may, in part, be due to a diverse range of genomic, epigenomic, proteomic, and metabolic alterations among individuals suffering from the same type of cancer. Precision medicine is an emerging approach in cancer therapeutics that takes into account specific molecular alterations, environmental factors as well as lifestyle of individual patients. This approach allows clinicians and researchers to select or predict treatments that would most likely benefit the patient based on their individual tumor characteristics. One class of precision medicine tools are predictive, in vitro drug-response assays designed to test the sensitivity of patient tumor cells to existing or novel therapies. These assays have the potential to rapidly identify the most effective treatments for cancer patients and thus hold great promise in the field of precision medicine. In this review, we have highlighted several drug-response assays developed in ovarian cancer and discussed the current challenges and future prospects of these assays in the clinical management of this disease.
View Full-Text
Keywords:
cancer therapeutics; precision medicine; drug response assays; tumor organoids; ovarian cancer; tumor spheroids
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Singh, T.; Neal, A.S.; Moatamed, N.A.; Memarzadeh, S. Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer. Int. J. Mol. Sci. 2021, 22, 305. https://doi.org/10.3390/ijms22010305
AMA Style
Singh T, Neal AS, Moatamed NA, Memarzadeh S. Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer. International Journal of Molecular Sciences. 2021; 22(1):305. https://doi.org/10.3390/ijms22010305
Chicago/Turabian StyleSingh, Tanya, Adam S. Neal, Neda A. Moatamed, and Sanaz Memarzadeh. 2021. "Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer" International Journal of Molecular Sciences 22, no. 1: 305. https://doi.org/10.3390/ijms22010305
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
